7Jackman AL, Melin CJ, Kimbell R, et al . A rationale for the clinical development of the thymdylate synthase inhibitor ZD9331 in ovarian and other solid tumours[J ]. Biochim Biophys Acta, 2002,1 587(7) : 215.
8Rader JS, Clarke - Pearson D, Morre M, et al. A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer [ J ] . Gynecol Oncol, 2003,91 ( 11 ) : 318.
9Smith D, Gallapher N. A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer[J ] .Eur J Cancer, 2003,39(7) : 1 377.
10Webber SE, Bleckman TM,Attard J, et al. Antiproliferative quinazolines : WO, 93/20055 [ P ] . 1993 - 10 - 14.
2Smith D, Gallapher N. A phase Ⅱ/Ⅲ study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer[J]. Eur J Cancer, 2003,39(7) :1377 - 1383.
3Mauritz R, Peters GJ, Priest DG. Et al. Multiple mechanisms of resistence to methotrexate and novel antifolates in human CCRFCEM leukemia cells and their implications for folate homeostasis[J]. Biochem Pharmacol,2002,63(2) :105 - 115.
4Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxd, pemetrexed and other newer agents inurothelial and kidney cancers[J]. Hematol Oncol,2003,46(2) :105 - 115.
5Dischof M, Huber P, Stoffregen C, et al. Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases[J]. Int J Radiat Oncol Biol Phys,2003, 57 (1) :289 -292.
6Kim SH, Brown SL, Kim JH. The potentiation of radiation response in human colon carcinoma cells in vitro and murine lymphoma in vitro by AG3379 (Thymitaq), a novel thymidylate synthase inhibitort [ J ]. Int J Radia Oncol Biol Phys, 1998, 42(4) :789 - 793.
7Costi MP, Tondi D, Rinaldi M. Structure-based studies on species-specific inhibition of thymidylate synthase[J ]. Biochim Biophys Acta, 2002,1587 (2): 206 - 214.
